BRPI0718118A2 - composições e métodos para ligação de sphingosine-1-fosfato - Google Patents
composições e métodos para ligação de sphingosine-1-fosfatoInfo
- Publication number
- BRPI0718118A2 BRPI0718118A2 BRPI0718118A BRPI0718118A BRPI0718118A2 BR PI0718118 A2 BRPI0718118 A2 BR PI0718118A2 BR PI0718118 A BRPI0718118 A BR PI0718118A BR PI0718118 A BRPI0718118 A BR PI0718118A BR PI0718118 A2 BRPI0718118 A2 BR PI0718118A2
- Authority
- BR
- Brazil
- Prior art keywords
- sphingosine
- compositions
- methods
- phosphate binding
- phosphate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US85497106P | 2006-10-27 | 2006-10-27 | |
| PCT/US2007/082647 WO2008070344A2 (en) | 2006-10-27 | 2007-10-26 | Compositions and methods for binding sphingosine-1-phosphate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0718118A2 true BRPI0718118A2 (pt) | 2017-05-30 |
Family
ID=39492938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0718118A BRPI0718118A2 (pt) | 2006-10-27 | 2007-10-26 | composições e métodos para ligação de sphingosine-1-fosfato |
Country Status (18)
| Country | Link |
|---|---|
| US (6) | US7829674B2 (pt) |
| EP (1) | EP2087002B1 (pt) |
| JP (2) | JP5795833B2 (pt) |
| KR (1) | KR101581279B1 (pt) |
| CN (2) | CN104650225B (pt) |
| AU (1) | AU2007329759B2 (pt) |
| BR (1) | BRPI0718118A2 (pt) |
| CA (1) | CA2667574A1 (pt) |
| DK (1) | DK2087002T3 (pt) |
| ES (1) | ES2524059T3 (pt) |
| IL (1) | IL198379A (pt) |
| MX (1) | MX2009004532A (pt) |
| PL (1) | PL2087002T3 (pt) |
| PT (1) | PT2087002E (pt) |
| RU (1) | RU2460541C2 (pt) |
| SI (1) | SI2087002T1 (pt) |
| WO (1) | WO2008070344A2 (pt) |
| ZA (1) | ZA200902860B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2667706A1 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| US20140186339A1 (en) * | 2006-10-27 | 2014-07-03 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
| EP2262528A2 (en) * | 2008-02-25 | 2010-12-22 | Expression Drug Designs, Llc. | Sphingosine 1-phosphate antagonism |
| US8212010B2 (en) | 2008-02-25 | 2012-07-03 | Expression Drug Designs, Llc | Sphingosine 1-phosphate antagonism |
| WO2009124294A2 (en) | 2008-04-05 | 2009-10-08 | Lpath, Inc. | Pharmaceutical compositions for binding sphingosine-1-phosphate |
| GB2461546B (en) * | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| US8444976B2 (en) | 2008-07-02 | 2013-05-21 | Argen-X B.V. | Antigen binding polypeptides |
| US8401799B2 (en) * | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| AU2009322185A1 (en) * | 2008-12-05 | 2011-07-21 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| EP2400981A4 (en) * | 2009-02-26 | 2013-02-27 | Lpath Inc | DESGIN FOR HUMANIZED THROMBOZYTE ACTIVATION FACTOR ANTIBODIES BY ANTI-LIPID ANTIBODY TEMPLATES |
| WO2010127069A1 (en) * | 2009-04-29 | 2010-11-04 | Schering Corporation | Antibody purification |
| AU2010292897B2 (en) | 2009-08-06 | 2016-01-07 | Genentech, Inc. | Method to improve virus removal in protein purification |
| GB2476681B (en) * | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| US20110212088A1 (en) * | 2010-02-26 | 2011-09-01 | Sabbadini Roger A | Anti-paf antibodies |
| WO2011109650A1 (en) * | 2010-03-03 | 2011-09-09 | The Board Of Trustees Of The University Of Illinois | Method of treating acute lung injury using sphingosine 1 phosphate analoges or sphingosine 1 phosphate receptor agonists |
| EP2563395A4 (en) | 2010-04-30 | 2013-11-27 | Lpath Inc | TREATMENT WITH ANTI-S1P ANTIBODY OF PATIENTS WITH OCULAR DISEASES |
| CA2801890A1 (en) * | 2010-06-06 | 2012-05-03 | Lpath, Inc. | Combinations of anti-s1p antibodies and sphingolipid pathway inhibitors |
| EP2598126A2 (en) | 2010-07-30 | 2013-06-05 | Saint Louis University | Methods of treating pain |
| WO2012072715A2 (en) * | 2010-12-01 | 2012-06-07 | Universität Zürich | Use of prokaryotic sphingosine-1-phosphate lyases and of sphingosine-1-phosphate lyases lacking a transmembrane domain for treating hyperproliferative and other diseases |
| JP5766958B2 (ja) * | 2011-01-21 | 2015-08-19 | オリンパス株式会社 | 顕微鏡システム、情報処理装置、及び情報処理プログラム |
| WO2012162392A1 (en) * | 2011-05-23 | 2012-11-29 | Timothy Hla | Endothelium protective materials and methods of use |
| CN103748450A (zh) | 2011-08-19 | 2014-04-23 | 马尔文仪器有限公司 | 双模式微粒表征 |
| JP6324376B2 (ja) | 2012-07-04 | 2018-05-16 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 抗テオフィリン抗体および使用方法 |
| BR112014030844A2 (pt) | 2012-07-04 | 2019-10-15 | Hoffmann La Roche | anticorpo anti-biotina humanizado, formulação farmacêutica e uso do anticorpo |
| BR112014029403A2 (pt) * | 2012-07-04 | 2018-10-09 | F. Hoffmann-La Roche Ag | conjugados, anticorpo e formulação farmacêutica |
| GB201300684D0 (en) | 2013-01-15 | 2013-02-27 | Apitope Int Nv | Peptide |
| EP2787006B1 (en) | 2013-04-02 | 2018-02-28 | Miltenyi Biotec GmbH | Anti-CD8 antibody which binding is Ca2+ dependent |
| ES2895752T3 (es) | 2014-01-03 | 2022-02-22 | Hoffmann La Roche | Anticuerpos biespecíficos anti-hapteno/anti-receptor de la barrera hematoencefálica, complejos de los mismos y su uso como lanzaderas a través de la barrera hematoencefálica |
| EP3089758B1 (en) | 2014-01-03 | 2021-01-27 | F.Hoffmann-La Roche Ag | Covalently linked helicar-anti-helicar antibody conjugates and uses thereof |
| EP3089759B1 (en) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Covalently linked polypeptide toxin-antibody conjugates |
| CN106687476B (zh) | 2014-06-26 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 抗brdu抗体及使用方法 |
| JP6716557B2 (ja) * | 2014-11-06 | 2020-07-01 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 浸出物および／または抽出物の除去のための活性炭 |
| US9754383B1 (en) * | 2014-12-22 | 2017-09-05 | Flagship Biosciences, Inc. | Automated methods for assessment of celiac disease |
| US10877045B2 (en) | 2015-07-21 | 2020-12-29 | Saint Louis University | Compositions and methods for diagnosing and treating endometriosis-related infertility |
| CN105820250B (zh) * | 2016-04-29 | 2019-04-30 | 中国人民解放军第四军医大学 | 一种抗basigin人源化抗体及其应用 |
| EP3554258B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate phosphorus or enzymes in a companion animal |
| ES2957464T3 (es) | 2017-04-14 | 2024-01-19 | Univ Arizona | Composiciones y métodos para tratar fibrosis pulmonar |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
Family Cites Families (145)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE1073471B (de) | 1958-09-02 | 1960-01-21 | Chemische Werke Hüls Aktiengesellschaft, Marl (Kr. Recklinghausen) | Verfahren zur Herstellung von Azelainsäure |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1573212A (en) | 1976-04-15 | 1980-08-20 | Technicon Instr | Immunoassay for gentamicin |
| USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| SE455445B (sv) | 1984-08-28 | 1988-07-11 | Pharmacia Ab | Antikroppar mot sialosyllaktotetraos (iv?723neuaclcose?714) och antikroppens resp antigenets anvendning vid tumordiagnostik |
| EP0173648A3 (en) | 1984-08-30 | 1988-04-27 | Ciba-Geigy Ag | New monoclonal antibodies to glycoconjugates, processes for their production, and applications |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) * | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4816450A (en) | 1986-09-15 | 1989-03-28 | Duke University | Inhibition of protein kinase C by long-chain bases |
| US4937232A (en) | 1986-09-15 | 1990-06-26 | Duke University | Inhibition of protein kinase C by long-chain bases |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| DE3741056A1 (de) | 1987-12-04 | 1989-08-24 | Behringwerke Ag | Manumycin-derivate, verfahren zu ihrer herstellung und ihre verwendung |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US20030229208A1 (en) | 1988-12-28 | 2003-12-11 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| US5151360A (en) | 1990-12-31 | 1992-09-29 | Biomembrane Institute | Effect of n,n,n-trimethylsphingosine on protein kinase-c activity, melanoma cell growth in vitro, metastatic potential in vivo and human platelet aggregation |
| US5248824A (en) | 1990-12-31 | 1993-09-28 | The Biomembrane Institute | Method of preparing N,N,N-trimethylsphingosine |
| US5137919A (en) | 1990-12-31 | 1992-08-11 | Biomembrane Institute | Effect of N,N,N,-trimethylsphingosine on protein kinase C activity melanoma cell growth in vitro; metastatic potential in vivo and human platelet aggregation |
| US5677288A (en) | 1991-05-15 | 1997-10-14 | Cypros Pharmaceutical Corporation | Use of aminoglycosides to protect against excitotoxic neuron damage |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| US5430160A (en) | 1991-09-23 | 1995-07-04 | Florida State University | Preparation of substituted isoserine esters using β-lactams and metal or ammonium alkoxides |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5932448A (en) | 1991-11-29 | 1999-08-03 | Protein Design Labs., Inc. | Bispecific antibody heterodimers |
| US5777085A (en) | 1991-12-20 | 1998-07-07 | Protein Design Labs, Inc. | Humanized antibodies reactive with GPIIB/IIIA |
| ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
| US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
| US6129914A (en) | 1992-03-27 | 2000-10-10 | Protein Design Labs, Inc. | Bispecific antibody effective to treat B-cell lymphoma and cell line |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5260288A (en) | 1992-04-03 | 1993-11-09 | The Biomembrane Institute | Method for inhibition of cell motility by sphingosine-1-phosphate and derivatives |
| US5369030A (en) | 1992-09-11 | 1994-11-29 | Duke University | Method of inducing cellular differentiations and altering cell phenotype using ceramide analogs |
| GB9223377D0 (en) | 1992-11-04 | 1992-12-23 | Medarex Inc | Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes |
| US6210671B1 (en) | 1992-12-01 | 2001-04-03 | Protein Design Labs, Inc. | Humanized antibodies reactive with L-selectin |
| US5444087A (en) | 1993-10-19 | 1995-08-22 | Bristol-Myers Squibb Company | Manumycin compounds |
| EP0729359A4 (en) | 1993-11-15 | 1999-06-02 | Baker Med Res Inst | METHOD FOR TREATING CARDIAC DYSFUNCTION AND PHARMACEUTICAL COMPOSITIONS FOR USE THEREFOR |
| GB9325182D0 (en) | 1993-12-08 | 1994-02-09 | T Cell Sciences Inc | Humanized antibodies or binding proteins thereof specific for t cell subpopulations exhibiting select beta chain variable regions |
| EP1008342A3 (en) | 1994-02-02 | 2004-12-29 | The Liposome Company, Inc. | Pharmaceutically active compounds and liposomes, and methods of use thereof |
| US5430169A (en) | 1994-02-14 | 1995-07-04 | The United States Of America Represented By The Department Of Health And Human Services | Method for preparation of sphingoid bases |
| US5585476A (en) | 1994-02-15 | 1996-12-17 | Maclennan; Alexander J. | Molecular cloning and expression of G-protein coupled receptors |
| US5627171A (en) | 1994-04-11 | 1997-05-06 | Oncomembrane, Inc. | Sphingosine-1-phosphate/trimethylsphingosine composition |
| US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
| US6323201B1 (en) | 1994-12-29 | 2001-11-27 | The Regents Of The University Of California | Compounds for inhibition of ceramide-mediated signal transduction |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US7060808B1 (en) | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
| US5667337A (en) | 1995-09-15 | 1997-09-16 | Lazes; Richard J. | Rotating containment and repelling boom and method for confining a material floatable on a liquid surface |
| US5916911A (en) | 1995-09-20 | 1999-06-29 | The Regents Of The University Of Michigan | Amino ceramide--like compounds and therapeutic methods of use |
| WO2001004108A1 (en) | 1999-07-09 | 2001-01-18 | Regents Of The University Of Michigan | Amino ceramide-like compounds and therapeutic methods of use |
| JPH09110722A (ja) | 1995-10-20 | 1997-04-28 | Toray Ind Inc | 抗腫瘍活性物質の腫瘍細胞内導入用イムノリポソーム及びその調製法 |
| US5882644A (en) | 1996-03-22 | 1999-03-16 | Protein Design Labs, Inc. | Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof |
| US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US5830916A (en) | 1996-05-23 | 1998-11-03 | Duke University | Inhibitor of ceramidase |
| DE19621038A1 (de) | 1996-05-24 | 1997-11-27 | Boehringer Ingelheim Kg | Aminoguanidine, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten |
| KR100468306B1 (ko) | 1996-07-19 | 2005-01-27 | 다카라 바이오 가부시키가이샤 | 스핑고지질 및 스핑고지질 유도체의 제조방법 |
| US6013256A (en) | 1996-09-24 | 2000-01-11 | Protein Design Labs, Inc. | Method of preventing acute rejection following solid organ transplantation |
| US6140060A (en) | 1996-12-12 | 2000-10-31 | Chun; Jerold J. M. | Cloned lysophosphatidic acid receptors |
| US5919687A (en) | 1996-12-24 | 1999-07-06 | John Hopkins University | Recombinant N-SMases and nucleic acids encoding same |
| US6235912B1 (en) | 1997-03-12 | 2001-05-22 | Takara Shuzo Co., Ltd. | Sphingosine analogues |
| EP0988552B1 (en) | 1997-06-10 | 2010-11-24 | Lpath, Inc. | Methods for early detection of heart disease |
| US6740512B1 (en) | 1997-08-11 | 2004-05-25 | Memorec Biotec Gmbh | Neutral sphingomyelinase |
| US5989803A (en) | 1997-09-05 | 1999-11-23 | The Trustees Of Columbia University In The City Of New York | Method for treating a subject suffering from a condition associated with an extracellular zinc sphingomyelinase |
| US6649362B2 (en) | 1997-09-08 | 2003-11-18 | Medvet Science Pty. Ltd. | Screening method for an agent having an effect on a sphingosine kinase signaling pathway |
| JP4091250B2 (ja) | 1997-09-11 | 2008-05-28 | タカラバイオ株式会社 | スフィンゴシン類誘導体及び医薬組成物 |
| US6423527B1 (en) | 1997-09-29 | 2002-07-23 | Children's Hospital Medical Center Of Northern California | Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| US6057126A (en) | 1997-12-24 | 2000-05-02 | Allelix Biopharmaceuticals, Inc. | Mammalian EDG-5 receptor homologs |
| JP2002501751A (ja) | 1998-01-29 | 2002-01-22 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 新規化合物 |
| CA2320117A1 (en) | 1998-02-12 | 1999-08-19 | Emory University | Sphingolipid derivatives and their methods of use |
| CA2315796C (en) | 1998-02-16 | 2004-03-09 | The Kitasato Institute | Novel substances kf-1040 and process for producing the same |
| US6423508B1 (en) | 1998-03-09 | 2002-07-23 | Smithkline Beecham Corporation | Polynucleotide sequences of human EDG-1c |
| CA2323787A1 (en) | 1998-03-13 | 1999-09-16 | Wayne Marasco | Humanized antibody and uses thereof |
| US6130067A (en) | 1998-05-20 | 2000-10-10 | Smithkline Beecham Corporation | Human EDG3sb gene |
| EP1235913A2 (en) | 1998-05-26 | 2002-09-04 | Sarah Spiegel | Sphingosine kinase, cloning, expression and methods of use |
| DE19828850A1 (de) | 1998-06-27 | 1999-12-30 | Gvs Ges Fuer Erwerb Und Verwer | Sphingolipid-Desaturase |
| EP1091745B1 (en) | 1998-06-29 | 2008-10-01 | Children's Hospital Of Los Angeles | Treatment of hyperproliferative disorders |
| DE19847149A1 (de) | 1998-10-13 | 2000-04-20 | Max Planck Gesellschaft | Pseudo-Ceramide |
| EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
| ATE330631T1 (de) | 1999-01-05 | 2006-07-15 | Univ Southern Australia | Antikörperfragmente zur lokalen behandlung von augenerkrankungen |
| AU2899900A (en) | 1999-03-02 | 2000-09-21 | Nps Allelix Corp. | Cloned human sphingosine kinase homologues |
| US6812335B1 (en) | 1999-03-23 | 2004-11-02 | The Regents Of The University Of California | Human polypeptide receptors for lysophospholipids and sphingolipids and nucleic acids encoding the same |
| AU2856499A (en) | 1999-03-25 | 2000-10-16 | Kitasato Institute, The | Novel substances kf-1040t4a, kf-1040t4b, kf-1040t5a and kf-1040t5b and process for producing the same |
| AU3326900A (en) | 1999-03-26 | 2000-10-16 | Takara Shuzo Co., Ltd. | Ceramidase gene |
| US7820718B1 (en) | 1999-04-07 | 2010-10-26 | Roger Williams Hospital | Combinations of ceramide and chemotherapeutic agents for inducing cell death and uses thereof in treating cancer |
| JP2000293181A (ja) | 1999-04-12 | 2000-10-20 | Daiichikosho Co Ltd | 歌詞画像描出機能に特徴を有するカラオケ装置 |
| IL145941A (en) * | 1999-04-28 | 2007-08-19 | Univ Texas | Compositions and methods for cancer treatment by selectively inhibiting vegf |
| ATE323153T1 (de) | 1999-05-13 | 2006-04-15 | Johnson & Johnson Pharm Res | Sphingosinekinase |
| DE19924148A1 (de) | 1999-05-26 | 2000-12-07 | Univ Heidelberg | Sphingomyelinasehemmer |
| WO2001004139A2 (en) | 1999-07-13 | 2001-01-18 | Smithkline Beecham Corporation | Human axor29 receptor |
| IT1307786B1 (it) | 1999-07-22 | 2001-11-19 | Bracco Spa | Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali. |
| WO2001031029A2 (en) | 1999-10-28 | 2001-05-03 | Warner-Lambert Company | Human sphingosine kinase gene |
| WO2001038295A1 (fr) | 1999-11-24 | 2001-05-31 | Taisho Pharmaceutical Co.,Ltd. | Derives de sphingosine |
| AU2001233086A1 (en) | 2000-01-28 | 2001-08-07 | Musc Foundation For Research Development | Ceramidase compositions and methods based thereon |
| JP2003521912A (ja) | 2000-02-07 | 2003-07-22 | メルク エンド カムパニー インコーポレーテッド | 哺乳動物スフィンゴシン−１−リン酸ホスファターゼ |
| US6306911B1 (en) | 2000-02-07 | 2001-10-23 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted amino acids as neutral sphingomyelinase inhibitors |
| CA2402148A1 (en) | 2000-02-14 | 2001-08-23 | Curagen Corporation | Novel sphingosine kinases |
| JP2001261575A (ja) | 2000-03-13 | 2001-09-26 | General Hospital Corp | 血管収縮を調節する方法とその組成物 |
| AU2001247755A1 (en) | 2000-03-23 | 2001-10-03 | Millennium Pharmaceuticals, Inc. | High throughput screening for inhibitors of fatty acid, ergosterol, sphingolipid, or phospholipid synthesis in fungi |
| AU2001255199A1 (en) | 2000-03-28 | 2001-10-08 | The Liposome Company, Inc. | Ceramide derivatives and method of use |
| WO2001080903A1 (en) | 2000-04-19 | 2001-11-01 | The Trustees Of Columbia University In The City Of New York | Detection and treatment of atherosclerosis based on plasma sphingomyelin concentration |
| AUPQ744700A0 (en) | 2000-05-11 | 2000-06-01 | Medvet Science Pty. Ltd. | A method of treatment and agents useful for same |
| US6571638B2 (en) | 2000-06-30 | 2003-06-03 | Sawtek, Inc. | Surface-acoustic-wave pressure sensor and associated methods |
| US20030125533A1 (en) | 2000-10-06 | 2003-07-03 | Sophia Kossida | Regulation of human sphingosine kinase-like protein |
| WO2002051439A2 (en) * | 2000-12-22 | 2002-07-04 | Medlyte, Inc. | Compositions and methods for the treatment and prevention of cardiovascular diseases and disorders, and for identifying agents therapeutic therefor |
| US20020150582A1 (en) | 2001-02-08 | 2002-10-17 | Friedrichs Gregory S. | Method of treating or inhibiting cellular injury or cell death |
| US7674580B2 (en) | 2002-01-17 | 2010-03-09 | Children's Hospital & Research Center At Oakland | Compositions and methods for the modulation of sphingolipid metabolism and/or signaling |
| US7794713B2 (en) * | 2004-04-07 | 2010-09-14 | Lpath, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| US7611851B2 (en) * | 2004-07-27 | 2009-11-03 | Merck & Co., Inc. | Canis sphingosine 1-phosphate receptor isoform 1 |
| AU2005325227B2 (en) * | 2004-10-28 | 2012-11-01 | Lpath Therapeutics, Inc. | Compositions and methods for the treatment and prevention of hyperproliferative diseases |
| WO2006104989A2 (en) | 2005-03-29 | 2006-10-05 | Verenium Corporation | Altered antibody fc regions and uses thereof |
| US20080213274A1 (en) * | 2005-10-28 | 2008-09-04 | Sabbadini Roger A | Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye |
| CA2667706A1 (en) * | 2006-10-27 | 2008-05-08 | Lpath, Inc. | Compositions and methods for treating ocular diseases and conditions |
-
2007
- 2007-10-26 DK DK07871262.7T patent/DK2087002T3/da active
- 2007-10-26 US US11/924,890 patent/US7829674B2/en not_active Expired - Fee Related
- 2007-10-26 EP EP07871262.7A patent/EP2087002B1/en active Active
- 2007-10-26 AU AU2007329759A patent/AU2007329759B2/en not_active Ceased
- 2007-10-26 PT PT78712627T patent/PT2087002E/pt unknown
- 2007-10-26 SI SI200731525T patent/SI2087002T1/sl unknown
- 2007-10-26 WO PCT/US2007/082647 patent/WO2008070344A2/en not_active Ceased
- 2007-10-26 ZA ZA200902860A patent/ZA200902860B/xx unknown
- 2007-10-26 RU RU2009120052/10A patent/RU2460541C2/ru not_active IP Right Cessation
- 2007-10-26 PL PL07871262T patent/PL2087002T3/pl unknown
- 2007-10-26 JP JP2009534885A patent/JP5795833B2/ja not_active Expired - Fee Related
- 2007-10-26 CN CN201510031165.XA patent/CN104650225B/zh not_active Expired - Fee Related
- 2007-10-26 KR KR1020097010728A patent/KR101581279B1/ko not_active Expired - Fee Related
- 2007-10-26 CA CA002667574A patent/CA2667574A1/en active Pending
- 2007-10-26 CN CN200780048665.8A patent/CN101679506B/zh not_active Expired - Fee Related
- 2007-10-26 BR BRPI0718118A patent/BRPI0718118A2/pt not_active IP Right Cessation
- 2007-10-26 ES ES07871262.7T patent/ES2524059T3/es active Active
- 2007-10-26 MX MX2009004532A patent/MX2009004532A/es active IP Right Grant
-
2008
- 2008-10-24 US US12/258,353 patent/US7956173B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,383 patent/US8026342B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,337 patent/US8067549B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,355 patent/US8025877B2/en not_active Expired - Fee Related
- 2008-10-24 US US12/258,346 patent/US8222373B2/en not_active Expired - Fee Related
-
2009
- 2009-04-26 IL IL198379A patent/IL198379A/en not_active IP Right Cessation
-
2015
- 2015-01-13 JP JP2015004493A patent/JP6053834B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200902860B (en) | Compositions and methods for binding sphingosine-1-phosphate | |
| PT2144998T (pt) | Métodos e composições para vírus vivos atenuados | |
| BRPI0815841A2 (pt) | Métodos e composições para melhoramento de traços preferidos. | |
| BRPI0716325A2 (pt) | Composição antimicrobianas | |
| BRPI0820980A2 (pt) | Composições e métodos para detecção de tiabs | |
| BRPI0817182A2 (pt) | Método para purificar um anticorpo e composições | |
| BRPI0812164A2 (pt) | Técnicas para provisão automática de software | |
| IL195619A0 (en) | Compositions and methods for joininig non-conjoined iumens | |
| DK2010501T3 (da) | Imidazolbaserede forbindelser, sammensætninger omfattende disse og fremgangsmåder for deres anvendelse | |
| BRPI0810525A2 (pt) | Composições e métodos para a profilaxia e tratamento de dependência química | |
| EP2043136A4 (en) | FILMING COMPOSITION | |
| CR10705A (es) | Anticuerpos para linfotoxina-alfa | |
| EP2003187A4 (en) | LUBRICANT COMPOSITIONS | |
| EP1988081A4 (en) | BINDING INHIBITOR OF SPHINGOSINE-1-PHOSPHATE | |
| FR2899479B1 (fr) | Composition cicatrisante | |
| DK1929865T3 (da) | Cyclopropensammensætninger | |
| EP2006359A4 (en) | GAS OIL COMPOSITION | |
| DE602007004823D1 (de) | Zusammensetzungen zur insektenbekämpfung | |
| BRPI0718035A2 (pt) | Método e disposição para fabricação de metanol | |
| BRPI0917375A2 (pt) | composicoes e metodos para fornecimento de um beneficio | |
| BRPI0812000A2 (pt) | Métodos e composições para administração de oxibutinina | |
| EP2006361A4 (en) | GAS OIL COMPOSITION | |
| EP2022839A4 (en) | GAS OIL COMPOSITION | |
| FR2898899B1 (fr) | Composition photoreticulable | |
| FI20060186A7 (fi) | Uudet koostumukset ja menetelmät niiden valmistamiseksi |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11Z | Dismissal: petition dismissal - article 216, par 2 of industrial property law |
Free format text: PROMULGA-SE O ARQUIVAMENTO DA PETICAO DE ENTRADA NA FASE NACIONAL POR INTEMPESTIVIDADE DE APRESENTACAO DA PROCURACAO CONFORME APRESENTADO NO ART. 216 2O DA LPI (LEI 9279/1996) E DA RESOLUCAO INPI-PR NO 77/2013, ART. 31. |
|
| B12C | Appeal against dismissal [chapter 12.3 patent gazette] | ||
| B15I | Others concerning applications: loss of priority | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2433 DE 22-08-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |